Skip to main content


Fig. 2 | Breast Cancer Research

Fig. 2

From: Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer

Fig. 2

Interferon (IFN)-γ+ anti-human epidermal growth factor receptor 2 (HER2) CD4+ T cell response variations in HER2pos patients with invasive breast cancer (IBC). IFN-γ enzyme-linked immunosorbent spot analysis of HER2 peptide-pulsed peripheral blood mononuclear cells examined anti-HER2 CD4+ T cell responses in patients with HER2pos IBC, stratified by anti-HER2 responsivity, response repertoire (mean # of reactive peptides), and cumulative response (mean total SFC/10 6 cells). Differences between (a) Treatment-naïve patients with HER2pos IBC (n = 22) and those treated with trastuzumab and chemotherapy (T + C) (n = 65); and (b) patients treated with Neoadjuvant T + C (n = 40) and those treated with Adjuvant T + C (n = 25). SFC spot-forming cells

Back to article page